What is Foldax?
Foldax is at the forefront of cardiac care innovation, developing TRIA heart valves engineered for superior durability and broader patient accessibility. Leveraging advanced biocompatible polymers and precision robotic manufacturing, the company aims to scale production efficiently. Foldax's technology addresses a critical need in the cardiovascular market, catering to a wide spectrum of patients, including younger demographics and those affected by conditions such as rheumatic heart disease. While TRIA Mitral Valves have gained approval in India, their availability in the United States is currently limited to investigational use, highlighting a key area for future growth and regulatory advancement.
How much funding has Foldax raised?
Foldax has raised a total of $34M across 4 funding rounds:
Series A
$3.4M
Series B
$10.3M
Debt
$350K
Series D
$20M
Series A (2016): $3.4M, investors not publicly disclosed
Series B (2018): $10.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $20M featuring Kairos Ventures, Caltech, BioStar Capital, Sayan Bioventures, Angel Physicians Fund, and MemorialCare
Key Investors in Foldax
Kairos Ventures
Kairos Ventures is an investment firm that appears to focus on companies aiming to improve people's lives, potentially in health and financial well-being, as suggested by their 'Make A Life' initiative.
MemorialCare
MemorialCare is a healthcare system with a long history, operating hospitals and outpatient facilities, indicating a strategic interest in medical advancements and patient care solutions.
Caltech
Caltech, likely referring to the California Institute of Technology, suggests an investment from an institution with a strong focus on scientific research and technological innovation.
What's next for Foldax?
The substantial enterprise-level backing positions Foldax for a pivotal growth phase. With a recent strategic investment, the company is poised to advance its clinical development, potentially expanding its investigational use in the U.S. and pursuing broader market approvals. This capital infusion will likely fuel further research and development into next-generation heart valve technologies, enhance manufacturing capabilities, and support strategic partnerships. Foldax's trajectory suggests a strong focus on scaling its operations to meet the global demand for advanced, durable, and accessible heart valve solutions, marking a significant step towards transforming cardiovascular treatment paradigms.
See full Foldax company page
